Evidence map›Paper›PMID 37686697›Full record

ArticleCancers2023

mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy.

Jamal Knaneh, Emmilia Hodak, Shlomit Fedida-Metula, Avishay Edri, Rachel Eren, Yael Yoffe, Iris Amitay-Laish, Hadas Prag Naveh, Ido Lubin, Angel Porgador and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jamal KnanehLaboratory for Molecular Dermatology, Felsenstein Medical Research Center, Tel Aviv 6997801, Israel.
Emmilia HodakLaboratory for Molecular Dermatology, Felsenstein Medical Research Center, Tel Aviv 6997801, Israel.
Shlomit Fedida-MetulaPiNK Biopharma Ltd., Ness Ziona 7403648, Israel.ORCID 0000-0001-6025-7359
Avishay EdriThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410101, Israel.ORCID 0000-0002-9232-6635
Rachel ErenPiNK Biopharma Ltd., Ness Ziona 7403648, Israel.
Yael YoffePiNK Biopharma Ltd., Ness Ziona 7403648, Israel.
Iris Amitay-LaishSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Hadas Prag NavehSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Ido LubinCore Facility, Felsenstein Medical Research Center, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Angel PorgadorThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410101, Israel.
Lilach MoyalLaboratory for Molecular Dermatology, Felsenstein Medical Research Center, Tel Aviv 6997801, Israel.
Tel Aviv University · ILBen-Gurion University of the Negev · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cutaneous T cell lymphoma (CTCL)monoclonal antibody 14 (mAb14)Mycosis fungoides (MF)natural killer p44 isoform-1 (NKp44-1)proliferating cell nuclear antigen (PCNA)Sézary syndrome (SS)

Identifiers

PMID37686697
PMCPMC10486495
OpenAlexW4386423414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.